Clinical trials
Lung Neoplasms trials in the United Kingdom with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
46 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 6 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 46 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Royal Marsden NHS Foundation Trust | 5 |
| The Christie NHS Foundation Trust | 4 |
| University of Glasgow | 3 |
| Manchester University NHS Foundation Trust | 2 |
| NHS Greater Glasgow and Clyde | 2 |
| National Cancer Institute (NCI) | 2 |
| The Clatterbridge Cancer Centre NHS Foundation Trust | 2 |
| University of Manchester | 2 |
| Belfast Health and Social Care Trust | 1 |
| CCTU- Cancer Theme | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Neoplasms | 46 |
| Carcinoma, Non-Small-Cell Lung | 17 |
| Neoplasms | 6 |
| Head and Neck Neoplasms | 3 |
| Melanoma | 3 |
| Small Cell Lung Carcinoma | 3 |
| Breast Neoplasms | 2 |
| Colorectal Neoplasms | 2 |
| Dyspnea | 2 |
| Fatigue | 2 |
Trials
Showing 1 to 25 of 46. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.